East Hannover

Nov 8, 2024 | academic.oup.com | Novartis Campus |John J. V |Baylor Heart |East Hannover

Heart failure (HF) outcomes reported by investigators in cardiovascular (CV) outcome trials are commonly referred for centralized adjudication by a blinded committee of clinical experts to select relevant clinical endpoints for analysis.1 This process has been encouraged by regulators on the premise that standardization of endpoint ascertainment through centralized review will both enhance the face validity of trial results and reduce bias by filtering the ‘noise’ of spurious events that...